Form 4: Pfizer Director Acquires Phantom Stock Units

Pfizer Director James C. Smith acquired 1,766.091 phantom stock units as deferred compensation, increasing his beneficial ownership to 161,563.412 units.

Summary

• James C. Smith, a Director at Pfizer Inc. (PFE), acquired 1,766.091 phantom stock units.
• The transaction date for this acquisition was September 30, 2025.
• Each phantom stock unit represents one phantom share of common stock.
• These units are part of deferred director's compensation, including dividend equivalents.
• The units will be settled in cash or common stock at the director's election upon retirement from the Board of Directors.
• The price of the derivative security (phantom stock unit) at the time of acquisition was $25.48.
• Following this transaction, James C. Smith beneficially owns a total of 161,563.412 phantom stock units.

Sentiment

Score: 6

Explanation: The filing indicates a routine compensation event for a director, which is generally neutral but can be seen as slightly positive due to continued alignment of director interests with the company's stock performance.

Positives

• The acquisition of phantom stock units aligns the director's interests with those of shareholders, as the value of these units is tied to Pfizer's common stock performance.
• This transaction represents a routine component of director compensation, indicating stable corporate governance practices.

Future Outlook

The filing does not contain forward-looking statements or guidance beyond the nature of the phantom stock units being settled upon the director's retirement.

Industry Context

The acquisition of phantom stock units as deferred compensation is a common practice in the pharmaceutical industry and across large public companies to incentivize and retain directors by aligning their long-term interests with shareholder value.

Comparison to Industry Standards

• Deferred equity-based compensation, such as phantom stock units, is a standard practice for director remuneration in large-cap companies like Pfizer, comparable to practices at peers such as Johnson & Johnson (JNJ) or Merck & Co. (MRK).
• The structure, where units are settled upon retirement, is typical for long-term incentive plans designed to foster sustained commitment and performance.

Related Party Transactions

• The acquisition of phantom stock units by James C. Smith, a Director, constitutes a related party transaction as it involves compensation provided by the issuer to a member of its board.

Stakeholder Impact

• Shareholders: The transaction demonstrates continued alignment of a director's financial interests with the company's stock performance, potentially fostering long-term value creation.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

This Form 4 filing details a routine compensation event for a director and does not provide new material information that would warrant a change in investment recommendation for Pfizer stock. It reflects standard corporate governance and compensation practices.

Keywords

Pfizer, PFE, Form 4, Insider Transaction, Director Compensation, Phantom Stock Units, Equity Compensation